Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters

A. Piffanelli, R. Dittadi, L. Catozzi, M. Gion, G. Capitanio, M. C. Gelli, A. Brazzale, R. Malagutti, D. Pelizzola, A. Menegon, G. Giovannini, G. Gardini

Research output: Contribution to journalArticle

Abstract

Four different methods to measure in parallel the erbB2 protein expression (p185(neu)) were evaluated in order to: a) compare two enzyme immunoassays with the immunohistochemical assays (IHC) and western blotting (WE) and b) extrapolate eventual relationships between erbB2 and biological parameters. Tissue samples from 248 patients with primary breast cancer were consecutively assayed. We used two different cut-off levels for WE, ELISA, and EIA, defined as follows: 1) the highest level of expression of non malignant tissue was chosen as the discriminant threshold between 'low' and 'elevated' samples: 2) the elevated group was further subdivided into two subgroups: 'intermediate' and 'high', according to their median value. According to the first cut-off, the results were considered 'elevated' in about 52% of cases with the three biochemical methods, while using the second cut-off the percentage lowered to about 26%. Considering this cut-off, the concordance rates between the paired biochemical methods ranged between: 78.4% (WE vs EIA), 93% (ELISA vs EIA), and 82.6% (ELISA vs WE). The comparison between biochemical and immunohistochemical methods gave these concordance rates: 82% (WE vs IHC), 90.5% (ELISA vs IHC), and 85.5% (EIA vs. IHC). According to the first cut off level, 27.5% of tumor samples showed IHC detectable p185 levels, in agreement with other immunohistochemical studies. The relationship between high erbB2 and estrogen and progesterone receptors showed an inverse association. No relationship was found between erbB2 and axillary lymph node positivity or tumor size. In short, the results of the four methods seem generally well correlated; nevertheless, it appears that different methodological approaches of measuring p185(neu) are not completely equivalent, and there is a need for an authoritative standardization and quality control for clinical applications.

Original languageEnglish
Pages (from-to)267-276
Number of pages10
JournalBreast Cancer Research and Treatment
Volume37
Issue number3
DOIs
Publication statusPublished - 1996

Fingerprint

Western Blotting
Breast Neoplasms
Enzyme-Linked Immunosorbent Assay
Proteins
Progesterone Receptors
Immunoenzyme Techniques
Estrogen Receptors
Quality Control
Neoplasms
Lymph Nodes

Keywords

  • Breast cancer
  • erbB2
  • Immunoenzymatic assays
  • Immunohistochemistry
  • Prognostic factor
  • Western blotting

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. / Piffanelli, A.; Dittadi, R.; Catozzi, L.; Gion, M.; Capitanio, G.; Gelli, M. C.; Brazzale, A.; Malagutti, R.; Pelizzola, D.; Menegon, A.; Giovannini, G.; Gardini, G.

In: Breast Cancer Research and Treatment, Vol. 37, No. 3, 1996, p. 267-276.

Research output: Contribution to journalArticle

Piffanelli, A, Dittadi, R, Catozzi, L, Gion, M, Capitanio, G, Gelli, MC, Brazzale, A, Malagutti, R, Pelizzola, D, Menegon, A, Giovannini, G & Gardini, G 1996, 'Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters', Breast Cancer Research and Treatment, vol. 37, no. 3, pp. 267-276. https://doi.org/10.1007/BF01806508
Piffanelli, A. ; Dittadi, R. ; Catozzi, L. ; Gion, M. ; Capitanio, G. ; Gelli, M. C. ; Brazzale, A. ; Malagutti, R. ; Pelizzola, D. ; Menegon, A. ; Giovannini, G. ; Gardini, G. / Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. In: Breast Cancer Research and Treatment. 1996 ; Vol. 37, No. 3. pp. 267-276.
@article{53b71a8b05254164b76a00d3a6a681bd,
title = "Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters",
abstract = "Four different methods to measure in parallel the erbB2 protein expression (p185(neu)) were evaluated in order to: a) compare two enzyme immunoassays with the immunohistochemical assays (IHC) and western blotting (WE) and b) extrapolate eventual relationships between erbB2 and biological parameters. Tissue samples from 248 patients with primary breast cancer were consecutively assayed. We used two different cut-off levels for WE, ELISA, and EIA, defined as follows: 1) the highest level of expression of non malignant tissue was chosen as the discriminant threshold between 'low' and 'elevated' samples: 2) the elevated group was further subdivided into two subgroups: 'intermediate' and 'high', according to their median value. According to the first cut-off, the results were considered 'elevated' in about 52{\%} of cases with the three biochemical methods, while using the second cut-off the percentage lowered to about 26{\%}. Considering this cut-off, the concordance rates between the paired biochemical methods ranged between: 78.4{\%} (WE vs EIA), 93{\%} (ELISA vs EIA), and 82.6{\%} (ELISA vs WE). The comparison between biochemical and immunohistochemical methods gave these concordance rates: 82{\%} (WE vs IHC), 90.5{\%} (ELISA vs IHC), and 85.5{\%} (EIA vs. IHC). According to the first cut off level, 27.5{\%} of tumor samples showed IHC detectable p185 levels, in agreement with other immunohistochemical studies. The relationship between high erbB2 and estrogen and progesterone receptors showed an inverse association. No relationship was found between erbB2 and axillary lymph node positivity or tumor size. In short, the results of the four methods seem generally well correlated; nevertheless, it appears that different methodological approaches of measuring p185(neu) are not completely equivalent, and there is a need for an authoritative standardization and quality control for clinical applications.",
keywords = "Breast cancer, erbB2, Immunoenzymatic assays, Immunohistochemistry, Prognostic factor, Western blotting",
author = "A. Piffanelli and R. Dittadi and L. Catozzi and M. Gion and G. Capitanio and Gelli, {M. C.} and A. Brazzale and R. Malagutti and D. Pelizzola and A. Menegon and G. Giovannini and G. Gardini",
year = "1996",
doi = "10.1007/BF01806508",
language = "English",
volume = "37",
pages = "267--276",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters

AU - Piffanelli, A.

AU - Dittadi, R.

AU - Catozzi, L.

AU - Gion, M.

AU - Capitanio, G.

AU - Gelli, M. C.

AU - Brazzale, A.

AU - Malagutti, R.

AU - Pelizzola, D.

AU - Menegon, A.

AU - Giovannini, G.

AU - Gardini, G.

PY - 1996

Y1 - 1996

N2 - Four different methods to measure in parallel the erbB2 protein expression (p185(neu)) were evaluated in order to: a) compare two enzyme immunoassays with the immunohistochemical assays (IHC) and western blotting (WE) and b) extrapolate eventual relationships between erbB2 and biological parameters. Tissue samples from 248 patients with primary breast cancer were consecutively assayed. We used two different cut-off levels for WE, ELISA, and EIA, defined as follows: 1) the highest level of expression of non malignant tissue was chosen as the discriminant threshold between 'low' and 'elevated' samples: 2) the elevated group was further subdivided into two subgroups: 'intermediate' and 'high', according to their median value. According to the first cut-off, the results were considered 'elevated' in about 52% of cases with the three biochemical methods, while using the second cut-off the percentage lowered to about 26%. Considering this cut-off, the concordance rates between the paired biochemical methods ranged between: 78.4% (WE vs EIA), 93% (ELISA vs EIA), and 82.6% (ELISA vs WE). The comparison between biochemical and immunohistochemical methods gave these concordance rates: 82% (WE vs IHC), 90.5% (ELISA vs IHC), and 85.5% (EIA vs. IHC). According to the first cut off level, 27.5% of tumor samples showed IHC detectable p185 levels, in agreement with other immunohistochemical studies. The relationship between high erbB2 and estrogen and progesterone receptors showed an inverse association. No relationship was found between erbB2 and axillary lymph node positivity or tumor size. In short, the results of the four methods seem generally well correlated; nevertheless, it appears that different methodological approaches of measuring p185(neu) are not completely equivalent, and there is a need for an authoritative standardization and quality control for clinical applications.

AB - Four different methods to measure in parallel the erbB2 protein expression (p185(neu)) were evaluated in order to: a) compare two enzyme immunoassays with the immunohistochemical assays (IHC) and western blotting (WE) and b) extrapolate eventual relationships between erbB2 and biological parameters. Tissue samples from 248 patients with primary breast cancer were consecutively assayed. We used two different cut-off levels for WE, ELISA, and EIA, defined as follows: 1) the highest level of expression of non malignant tissue was chosen as the discriminant threshold between 'low' and 'elevated' samples: 2) the elevated group was further subdivided into two subgroups: 'intermediate' and 'high', according to their median value. According to the first cut-off, the results were considered 'elevated' in about 52% of cases with the three biochemical methods, while using the second cut-off the percentage lowered to about 26%. Considering this cut-off, the concordance rates between the paired biochemical methods ranged between: 78.4% (WE vs EIA), 93% (ELISA vs EIA), and 82.6% (ELISA vs WE). The comparison between biochemical and immunohistochemical methods gave these concordance rates: 82% (WE vs IHC), 90.5% (ELISA vs IHC), and 85.5% (EIA vs. IHC). According to the first cut off level, 27.5% of tumor samples showed IHC detectable p185 levels, in agreement with other immunohistochemical studies. The relationship between high erbB2 and estrogen and progesterone receptors showed an inverse association. No relationship was found between erbB2 and axillary lymph node positivity or tumor size. In short, the results of the four methods seem generally well correlated; nevertheless, it appears that different methodological approaches of measuring p185(neu) are not completely equivalent, and there is a need for an authoritative standardization and quality control for clinical applications.

KW - Breast cancer

KW - erbB2

KW - Immunoenzymatic assays

KW - Immunohistochemistry

KW - Prognostic factor

KW - Western blotting

UR - http://www.scopus.com/inward/record.url?scp=1542741308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542741308&partnerID=8YFLogxK

U2 - 10.1007/BF01806508

DO - 10.1007/BF01806508

M3 - Article

C2 - 8825138

AN - SCOPUS:1542741308

VL - 37

SP - 267

EP - 276

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -